Glenmark Pharmaceuticals Launches Clindamycin Phosphate Foam, 1% For Acne Treatment

(RTTNews) - India-based Glenmark Pharmaceuticals Inc.'s USA subsidiary, Thursday announced the launch of Clindamycin Phosphate Foam, 1 percent for the treatment of acne.

The company added that Clindamycin Phosphate Foam, 1 percent is bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin Foam, 1 percent, of Mylan Pharmaceuticals Inc.

Notably, the Evoclin Foam, 1 percent market reported annual sales of approximately $5.8 million, according to IQVIA sales data for the 12-month period ending December 2024.

Thursday, Glenmark closed at INR 1,411.20, up 0.36 percent on the National Stock Exchange.